pharmaceuticals

95992888

Did Biogen Run Too Much After Earnings?

Biogen Idec Inc. (NASDAQ: BIIB) announced its fourth-quarter financials Thursday after the markets closed. The company reported revenue of $2.6 billion, up 34% from the fourth quarter of the previous year. Revenues ...
Read Full Story »
462542665

Are Humira Sales Enough to Lift AbbVie?

AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter financial results Friday before the markets open. This drug manufacturing giant posted earnings per share (EPS) of $0.89 and $5.37 billion in revenue. ...
Read Full Story »
Money background. Close-up.

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported its fourth-quarter results on Thursday morning. The biotech giant did beat earnings, but investors have to weigh whether it was enough when you consider that ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Pfizer logo

Pfizer Faces Reality Check With Earnings

Pfizer Inc. (NYSE: PFE) reported its fourth-quarter results Tuesday before the markets open as $0.54 in earnings per share (EPS) and $13.1 billion in revenue. That compared to Thomson Reuters ...
Read Full Story »
Pills

Is a Generic Nexium Purple Pill for You?

When it comes to drugs being overly advertised, the Purple Pill, or Nexium, has been advertised over and over for years now. Now the question to ask is if a ...
Read Full Story »
Shake Shack IPO

Shake Shack Leads the Parade of IPOs Scheduled for Next Week

Initial public offerings (IPO) were a bit slow getting off the mark in 2015, but the week of January 26 looks ready to make up for the tepid start. A ...
Read Full Story »
research

3 Biotech Stocks With Upcoming Data That Could Be Huge

Binary events are often the key element in moving a biotech stock higher. Negative binary results or actions can often move shares drastically lower, though. We scan our 24/7 Wall ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Barely Pulls Through on Strong Pharma Sales

Johnson & Johnson (NYSE: JNJ) reported its fourth-quarter results Tuesday before the market open as $1.27 in earnings per share (EPS) on $18.6 billion in revenue. That was against Thomson ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
462542665

Celgene Expects to More Than Triple Earnings by 2020

Celgene Corp. (NASDAQ: CELG) provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare ...
Read Full Story »
payoff

Is the Merger a Great Deal for Tekmira Shareholders?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), in conjunction with OnCore Biopharma, announced that they have agreed to merge and create a new global hepatitis B virus (HBV) company. The focus of ...
Read Full Story »
Pfizer logo

The Bullish and Bearish Case for Pfizer in 2015

Last year was another great one for a bull market that is nearly six years old. The Dow Jones Industrial Average (DJIA) rose 7.5% and the S&P 500 Index rose ...
Read Full Story »
Money background. Close-up.

Gilead Continues to Recover from Express Scripts Loss

After the markets closed on Thursday, Gilead Sciences Inc. (NASDAQ: GILD) was picked up by Anthem Inc. (NYSE: ANTM) to provide its hepatitis C drug as the primary option for ...
Read Full Story »
biotech

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

With a strong market rally getting the markets just about back to even to the start of 2015, aggressive investors are looking ahead to fourth-quarter earnings and other catalysts to ...
Read Full Story »